From Nasdaq:

The pandemic continues to recede, resulting in a diminished need for COVID-19 vaccines and medications. Moderna’s financial performance took a hit in 2023 due to reduced sales, but new product approvals are on the horizon. New vaccines for respiratory syncytial virus (RSV) and other promising candidates in their late-stage pipeline could drive future sales growth. Analysts suggest that these new products could generate billions in revenue. Investors and analysts expect Moderna’s sales to stabilize and return to top-line growth by 2025, making it a potentially attractive long-term investment opportunity.



Read more: 1 Stock Down 43% to Buy and Hold for 10 Years